Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A Clinical Study to Determine the Pharmacokinetics of Oraxol in Breast Cancer Patients

Trial Profile

A Clinical Study to Determine the Pharmacokinetics of Oraxol in Breast Cancer Patients

Status: Recruiting
Phase of Trial: Phase I

Latest Information Update: 04 Jun 2019

Price : $35 *
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Encequidar+paclitaxel-Athenex (Primary)
  • Indications Advanced breast cancer
  • Focus Pharmacokinetics
  • Sponsors Athenex
  • Most Recent Events

    • 04 Jun 2019 Results (n=28) presented at the 55th Annual Meeting of the American Society of Clinical Oncology
    • 22 Oct 2018 Results presented in an Athenex media release.
    • 22 Oct 2018 According to an Athenex media release, data from was presented at the European Society for Medical Oncology (ESMO) Congress 2018.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top